Use of immunotherapy in the treatment of a patient with two simultaneous metastatic diseases

Immunotherapy is an evolving and promising cancer treatment proven to significantly prolong survival in a multitude of oncological diseases. Nivolumab, a monoclonal antibody to the PD-1 receptor, is an immunotherapy used in the treatment of several cancers, including melanoma and renal cell carcinoma (RCC).